Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SP 16

Next Previous
Drug Profile

SP 16

Alternative Names: Serpin Peptide 16; SP-16

Latest Information Update: 06 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Serpin Pharma
  • Developer Serpin Pharma; Virginia Commonwealth University
  • Class Analgesics; Anti-inflammatories; Anti-ischaemics; Antihyperglycaemics; Cardiovascular therapies; Oligopeptides; Peptides; Serpins; Skin disorder therapies
  • Mechanism of Action Immunomodulators; LDL receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Inflammation; Myocardial infarction; SARS-CoV-2 acute respiratory disease
  • Preclinical Acute kidney injury; Atopic dermatitis; Chronic inflammatory demyelinating polyradiculoneuropathy; Eosinophilic oesophagitis
  • Research Alopecia areata; Neuropathic pain; Pemphigus vulgaris
  • No development reported Diabetes mellitus; Myocardial reperfusion injury

Most Recent Events

  • 29 Sep 2025 Dogwood Therapeutics and Serpin Pharma agree to co-develop SP 16 for Chemotherapy-induced neuropathic pain
  • 29 Sep 2025 Serpin Pharma plans a phase Ib trial for Chemotherapy induced neuropathy in first half of 2026
  • 23 May 2024 Serpin Pharma terminates a phase I/II trial in SARS-COV-2 acute respiratory disease in USA (SC), due to lack of patients (NCT05135624)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top